Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis
Lei Hong, Yue Yang, Yuwen Han, Nan Ouyang, Minxuan Sun, Rongchuan Zhao · 2026
Read Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis by Lei Hong, Yue Yang, Yuwen Han, Nan Ouyang, Minxuan Sun, Rongchuan Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13439533.txt.
Description
Lei Hong and co-authors report a protective role for the protein NPM1 inside tumour-associated macrophages, publishing mouse cancer work in 2026. NPM1 is famous as a leukaemia gene, but its part in solid tumour immunity was little known. Blocking or reducing NPM1 sped growth of colon and lung tumours implanted in mice. Tumours in those mice drew in more suppressive M2-like macrophages, a wound-healing type that shelters cancer, while killer T cells worked poorly.
Gene tracing showed NPM1 partners with the signal protein STAT3 to switch on CCRL2, a regulator of macrophage behaviour. Raising NPM1 levels in mice flipped the pattern: tumours grew less, suppressive macrophages fell away, and killer T cell attack strengthened. The authors frame the STAT3-CCRL2 axis as a lever for rearming immunity inside solid tumours.
Catalog record
| CREATOR | Lei Hong, Yue Yang, Yuwen Han, Nan Ouyang, Minxuan Sun, Rongchuan Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34948 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |